Humalog Lispro 100 Iu/ml 3 ML Cartridge

Humalog Lispro 100 Iu/ml 3 ML Cartridge is a prescription based medicine with Insulin Lispro (100IU/ml) as an active ingredient. It is used to treat type 1 and type 2 diabetes mellitus by improving blood sugar control. Humalog Lispro is a fast-acting type of insulin which helps to minimize the blood sugar levels after meals and also decrease the chances of developing serious complications of diabetes. It is commonly prescribed along with a long-acting type of insulin or other diabetes medicines.

• Type 1 and Type 2 diabetes mellitus

Like any other medicine, Humalog Lispro 100 Iu/ml 3 ML also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include:

• Low blood sugar (Hypoglycaemia)
• Light headedness
• Dizziness
• Anxiety
• Nervousness
• Tiredness
• Feeling hungry
• Visual disturbances
• Headache
• Shaking
• Sweating
• Pale skin
• Skin rashes
• Pain, redness, swelling at injection site.

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Dosage of this injection determined by the doctor as per the type of disease and overall health condition of the patient. Correct way of injecting Humalog Lispro 100 Iu/ml 3 ML under the skin teach by your healthcare provider.
• It should be taken 15 minutes before a meal or within 20 minutes after starting a meal. Do not stop the medication without doctor's advice.
  
  

• Humalog Lispro 100 Iu/ml 3 ML Cartridge is a fast-acting insulin with Insulin Lispro (100IU/ml) as an active ingredient. It starts working within 10-20 minutes after injecting. This injection acts similarly as like the insulin produced by the body.
• Insulin facilitates reuptake of glucose in muscle and fat cells and also blocks the release of glucose from the liver.
  
  

• Chen, J. W., Christiansen, J. S., & Lauritzen, T. (2003). Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes, Obesity & Metabolism, 5(4). https://pubmed.ncbi.nlm.nih.gov/12795655/
• Godman, B., Leong, T., Abubakar, A. R., Kurdi, A., Kalemeera, F., Rwegerera, G. M., ... & Ogunleye, O. (2021). Availability and use of long-acting insulin analogues including their biosimilars across Africa; findings and implications. Internal Medicine, 11(4), 100343. https://www.longdom.org/open-access/availability-and-use-of-longacting-insulin-analogues-including-their-biosimilars-across-africa-findings-and-implications-83849.html
• Dutta, D., Mohindra, R., Mahajan, K., & Sharma, M. (2023). Performance of fast-acting aspart insulin as compared to aspart insulin in insulin pump for managing type 1 diabetes mellitus: a meta-analysis. Diabetes & Metabolism Journal, 47(1), 72-81. https://pubmed.ncbi.nlm.nih.gov/35746893/
• Pajaziti, B., Petkovska, R., Andrási, M., & Nebija, D. (2020). Application of the capillary zone electrophoresis (CZE) and capillary gel electrophoresis (CGE) for the separation of human insulin, insulin lispro and their degradation products. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 75(5), 167-171. https://pubmed.ncbi.nlm.nih.gov/32393421/
• Zargar, A. A., Kumar, R., Kumar, A., Gangwar, R., & Sharma, A. (2024). Centenary of Insulin Therapy: A Review. Current Diabetes Reviews, 20(1), 6-18. https://pubmed.ncbi.nlm.nih.gov/36959148/